Safusidenib Shows 44% Response Rate and Long-Term Disease Control in Nuvation Bio Phase 2 Study
Market Chameleon (Wed, 3-Dec 8:35 AM)
Top Executive Sells Massive Shares in Nuvation Bio!
at www.tipranks.com (Wed, 3-Dec 9:05 PM)
Nuvation Bio Announces Participation in Two Major Healthcare Investor Conferences
Market Chameleon (Fri, 28-Nov 8:17 AM)
Nuvation Bio Launches Pivotal TRUST-IV Phase 3 Study for IBTROZI in Early-Stage ROS1+ NSCLC
Market Chameleon (Tue, 30-Sep 11:18 AM)
